---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-17T18:30:11.241330'
end_time: '2025-12-17T18:36:16.429486'
duration_seconds: 365.19
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Parkinson's Disease
  mondo_id: ''
  category: Complex
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 15
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Parkinson's Disease
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Parkinson's Disease**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Parkinson's Disease
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Parkinson's Disease**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


Plan status (concise): I compiled recent, authoritative sources (2023–2025), synthesized core mechanisms, mapped key genes/proteins and processes to standard ontologies, linked mechanisms to disease stages and phenotypes, and summarized current applications, expert analysis, and epidemiology. Citations with URLs and publication dates are provided.

Disease Pathophysiology Research Report

Target Disease
- Disease Name: Parkinson’s disease (PD)
- MONDO ID: MONDO:0005180
- Category: Complex

1) Core Pathophysiology: current understanding
- Alpha‑synuclein misfolding, aggregation, and propagation: PD pathogenesis centers on abnormal alpha‑synuclein (SNCA) aggregation into Lewy bodies/neurites with prion‑like spread across neural networks. Evidence integrates genetics (SNCA dosage/mutations), neuropathology (Lewy inclusions capturing mitochondria/lysosomes), and in vivo propagation models. As a recent authoritative review states: “abnormal alpha‑synuclein aggregation and spreading between gut, brainstem and higher brain regions [is] a likely substrate for disease initiation and progression,” with oligomers likely more toxic than large aggregates (The Lancet, Jan 2024; doi:10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4). See also (morris2024thepathogenesisof pages 4-7, bai2025updatesonparkinson’s pages 7-8).
- Mitochondrial dysfunction and mitophagy failure: Fundamental mitochondrial deficits (complex I impairment, ROS, ATP shortfall) occur early, interlinked with PINK1/Parkin mitophagy pathways; environmental complex I inhibitors (e.g., MPTP/pesticides) converge on this axis (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4).
- Lysosomal/autophagy and endo‑lysosomal trafficking defects: Genetics and pathway data implicate lysosomal pathways (e.g., GBA1, LRRK2, VPS35), with impaired proteostasis driving alpha‑syn accumulation (Lancet 2024; 2024 IJMS review) (morris2024thepathogenesisof pages 1-4, alvarez2024acomprehensiveapproach pages 2-4).
- Neuroinflammation and glial crosstalk: Chronic microglial/astrocytic activation, cytokine cascades, and gut–brain immune signaling likely contribute to progression; immune‑inflammatory mechanisms are highlighted as key but incompletely resolved (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). 
- Calcium homeostasis, synaptic and axonal dysfunction: Early synaptic injury (vesicle trafficking, axonal transport) and calcium dysregulation precede neuronal loss, particularly in vulnerable nigrostriatal dopaminergic neurons (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4).
- Body‑first vs brain‑first and gut–brain axis: Both Braak’s peripheral‑to‑central model and a “brain‑first” trajectory are supported; prodromal autonomic/GI features and RBD support a body‑first subtype in a substantial subgroup (Lancet 2024; 2025 narrative synthesis) (morris2024thepathogenesisof pages 1-4, tanaka2025parkinson’sdiseasebridging pages 6-7, chaudhary2025understandingparkinson’sdisease pages 2-3).

2) Key Molecular Players
- Genes/Proteins (HGNC):
  - SNCA (alpha‑synuclein): causal; mutations/dosage increase aggregation and drive aggressive phenotypes (Lancet 2024) (morris2024thepathogenesisof pages 1-4).
  - LRRK2 (PARK8): most common Mendelian PD; kinase activity implicated; variants (e.g., G2019S, R1441) and downstream lysosomal/endolysosomal effects (Lancet 2024; IJMS 2024) (morris2024thepathogenesisof pages 1-4, alvarez2024acomprehensiveapproach pages 2-4).
  - PRKN (Parkin; PARK2), PINK1 (PARK6): recessive; central to mitophagy, mitochondrial quality control (Lancet 2024) (morris2024thepathogenesisof pages 1-4).
  - PARK7 (DJ‑1): recessive; oxidative stress responses (IJMS 2024) (alvarez2024acomprehensiveapproach pages 2-4).
  - GBA1 (glucocerebrosidase): strongest risk factor among lysosomal enzyme genes; glucosylceramide handling, autophagy‑lysosomal pathways (Lancet 2024) (morris2024thepathogenesisof pages 1-4).
  - VPS35: endosomal trafficking; links to lysosome/autophagy (Lancet 2024) (morris2024thepathogenesisof pages 1-4).
  - Polygenic risk: “90 independent variants across 74 genomic loci” implicating lysosome–autophagy and immune pathways (Lancet 2024) (morris2024thepathogenesisof pages 1-4).
- Chemical entities (CHEBI) and modulators:
  - Dopamine (CHEBI:18243): neurotransmitter depleted in striatum; levodopa remains pivotal symptomatic therapy (IJMS 2024) (alvarez2024acomprehensiveapproach pages 2-4).
  - Glucosylceramide (CHEBI:18238): substrate in GBA1 pathway; links lipid metabolism to alpha‑syn burden (Lancet 2024) (morris2024thepathogenesisof pages 1-4).
  - Alpha‑synuclein‑targeting biologics and small molecules: therapeutic development ongoing (NDT 2025) (bai2025updatesonparkinson’s pages 1-2).
  - LRRK2 kinase inhibitors: BBB‑penetrant candidates entering clinical testing (NDT 2025) (bai2025updatesonparkinson’s pages 1-2).
- Cell types (CL):
  - Midbrain dopaminergic neuron, substantia nigra pars compacta (CL:0002609): selectively vulnerable (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4).
  - Microglia (CL:0000129) and astrocytes (CL:0000127): drivers and modulators of neuroinflammation (Lancet 2024) (morris2024thepathogenesisof pages 1-4).
  - Enteric neurons/glia (ENS): peripheral initiation sites in body‑first subtype (Lancet 2024) (morris2024thepathogenesisof pages 1-4).
- Anatomical locations (UBERON):
  - Substantia nigra pars compacta (UBERON:0002038), striatum (UBERON:0002435): canonical motor circuit pathology (Lancet 2024) (morris2024thepathogenesisof pages 4-7).
  - Olfactory bulb (UBERON:0002312); dorsal motor nucleus of vagus (UBERON:0002826); enteric nervous system (UBERON:0007250): prodromal/peripheral staging nodes (Lancet 2024) (morris2024thepathogenesisof pages 1-4).

3) Biological Processes (GO) disrupted
- Protein aggregation and amyloid fibril formation; synaptic vesicle cycle; axonal transport; calcium ion homeostasis (GO:0006816); oxidative phosphorylation and response to oxidative stress (GO:0006979); mitophagy (GO:0000423) and mitochondrial fission/fusion; autophagy (GO:0006914) and lysosomal organization; innate immune signaling and microglial activation. Mechanistic reviews emphasize mitochondria–ER–lysosome network disruption, with alpha‑syn propagating pathology across these systems (Lancet 2024; Cells 2025) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4, tanaka2025parkinson’sdiseasebridging pages 6-7).

4) Cellular Components (GOCC)
- Presynaptic terminals (alpha‑syn physiology/pathology), Lewy bodies/neurites (cytoplasmic inclusions capturing organelles), mitochondria, lysosomes, endosomes, ER, synaptic vesicles. Lewy bodies “trap organelles including mitochondria and lysosomes,” linking aggregation to organellar dysfunction (Lancet 2024, Jan 2024; doi link below) (morris2024thepathogenesisof pages 4-7).

5) Disease Progression and Staging
- Sequence of events: prodrome → early synaptic/metabolic stress → alpha‑syn oligomer accumulation and fibril formation → organellar (mitochondria/lysosome) stress and impaired mitophagy → neuroinflammation/glial activation → progressive nigrostriatal degeneration and network spread → clinical motor syndrome and expanding non‑motor burden (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4).
- Braak staging and heterogeneity: classical six‑stage model proposes initial lesions in olfactory bulb/ENS with ascending spread; however, “many cases do not follow Braak staging,” and a brain‑first subtype also exists, underscoring divergent pathways (Lancet 2024) (morris2024thepathogenesisof pages 1-4). Body‑first vs brain‑first dichotomy and prodromal subtypes are emphasized in 2025 expert synthesis advocating biological definitions and prevention‑trial design (Cells 2025, Jul 2025; doi:10.3390/cells14151161) (tanaka2025parkinson’sdiseasebridging pages 6-7).
- Prodromal markers: REM sleep behavior disorder (RBD), anosmia, constipation/autonomic dysfunction, subtle cognitive/affective changes are integrated into MDS criteria for prodromal PD (Lancet 2024) (morris2024thepathogenesisof pages 1-4). 

6) Phenotypic Manifestations (HP terms)
- Motor: bradykinesia (HP:0002067), rigidity (HP:0002063), resting tremor (HP:0002322), gait disturbance/postural instability (HP:0002066). These reflect nigrostriatal dopamine loss and basal ganglia circuit plasticity changes (Lancet 2024) (morris2024thepathogenesisof pages 4-7).
- Non‑motor: hyposmia (HP:0004408), constipation (HP:0002019), orthostatic hypotension (HP:0001278), REM sleep behavior disorder (HP:0002362), depression/anxiety (HP:0000716/HP:0000739), cognitive impairment/dementia (HP:0100543/HP:0000726). These map to early involvement of olfactory, autonomic and limbic systems and widespread network pathology (Lancet 2024; Cells 2025) (morris2024thepathogenesisof pages 1-4, tanaka2025parkinson’sdiseasebridging pages 6-7).

7) Biomarkers and clinical tools (with URLs/dates)
- Alpha‑synuclein seed amplification assays (SAA/RT‑QuIC): Biomarker panels now include α‑syn SAA from CSF or minimally invasive tissues; reviews highlight SAA’s high diagnostic performance in manifest/prodromal cohorts, while stressing standardization and access limitations. Notably, “alpha‑synuclein seed amplification assays…are being used clinically for biochemical diagnosis” in synucleinopathies, although broader deployment requires harmonization (published 2025/2024 syntheses) (NDT 2025, Sep 2025, https://doi.org/10.2147/ndt.s540718; Lancet 2024, Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (bai2025updatesonparkinson’s pages 1-2, morris2024thepathogenesisof pages 1-4). A 2025 synthesis also emphasizes SAA utility within biomarker‑driven definitions and prevention trials (Cells 2025, Jul 2025, https://doi.org/10.3390/cells14151161) (tanaka2025parkinson’sdiseasebridging pages 6-7).
- Imaging: Dopamine transporter (DAT) SPECT and advanced PET tracers delineate dopaminergic degeneration; neuromelanin and iron‑sensitive MRI support staging; multimodal imaging of inflammation and neurotransmitters is expanding for prodrome (Lancet 2024; NDT 2025) (https://doi.org/10.1016/S0140-6736(23)01478-2; https://doi.org/10.2147/ndt.s540718) (morris2024thepathogenesisof pages 1-4, bai2025updatesonparkinson’s pages 1-2).
- Emerging alpha‑syn PET: First clinical alpha‑syn PET signals are reported in specific synucleinopathies and are anticipated to expand; timelines and challenges are discussed as part of a broader biomarker roadmap toward biological PD definitions (Cells 2025, Jul 2025) (tanaka2025parkinson’sdiseasebridging pages 6-7). 
- Digital biomarkers: Wearables and remote sensing aid motor/non‑motor phenotyping and may enrich trials; “digital phenotyping” can predict fluctuations and support early detection, though validation and equity are needed (NDT 2025, Sep 2025) (bai2025updatesonparkinson’s pages 1-2).

8) Current applications and real‑world implementations
- Clinical practice: Combined use of clinical criteria (MDS), dopaminergic imaging when indicated, and selective application of fluid/tissue α‑syn SAA is growing in expert centers; expert reviews call for standardization and access expansion (Lancet 2024; NDT 2025) (morris2024thepathogenesisof pages 1-4, bai2025updatesonparkinson’s pages 1-2).
- Trials and pipelines: Disease‑modifying strategies include α‑syn immunotherapies, lysosomal/mitophagy enhancers, and kinase modulators (e.g., LRRK2 inhibitors). Expert pipeline summaries highlight BBB‑penetrant LRRK2 inhibitors and α‑syn therapies progressing through phase II, with trial design evolving toward prodromal/biological staging (NDT 2025, Sep 2025; Cells 2025, Jul 2025) (bai2025updatesonparkinson’s pages 1-2, tanaka2025parkinson’sdiseasebridging pages 6-7).
- Prevention framing: Given prodromal biomarkers (SAA, imaging, genetics), secondary prevention trials are advocated, with subtype‑specific enrichment (e.g., RBD cohorts, genetic carriers) (Cells 2025, Jul 2025) (tanaka2025parkinson’sdiseasebridging pages 6-7).

9) Expert opinions and analysis (authoritative sources, 2023–2025)
- The Lancet 2024 review synthesizes genetics, organellar pathology, immune mechanisms, and heterogeneity, concluding: “There are currently no disease‑modifying treatments, but mechanistic insights… provide a basis for targeted neuroprotective strategies” (Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4).
- Recent expert syntheses emphasize a shift to biological definitions integrating α‑syn SAA/imaging, genetics, and digital phenotyping, and call for prevention‑trial designs and equitable biomarker access (Cells 2025, Jul 2025, https://doi.org/10.3390/cells14151161; NDT 2025, Sep 2025, https://doi.org/10.2147/ndt.s540718) (tanaka2025parkinson’sdiseasebridging pages 6-7, bai2025updatesonparkinson’s pages 1-2).

10) Relevant statistics and recent epidemiology (2019–2024)
- Global burden: PD affects “over ten million individuals” worldwide, with rising prevalence over the last decade and incidence typically 8–18 per 100,000 person‑years; male predominance ~1.5×; early‑onset PD 5–10% (NDT 2025, Sep 2025, https://doi.org/10.2147/ndt.s540718) (bai2025updatesonparkinson’s pages 1-2). Contemporary global analyses cited by these reviews corroborate increasing age‑standardized prevalence and regional heterogeneity (Lancet 2024, Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4).

Structured Annotations for a Knowledge Base
- Pathophysiology (summary): Aggregated α‑synuclein seeds propagate across neural/peripheral networks, impairing synapses and organellar homeostasis (mitochondria–lysosome–ER). Mitophagy failure (PINK1/PRKN) and lysosomal dysfunction (GBA1, LRRK2, VPS35) amplify proteostasis stress and neuroinflammation, culminating in nigrostriatal degeneration and widespread network involvement (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4).
- Gene/Protein annotations (HGNC): SNCA; LRRK2; PRKN; PINK1; PARK7; GBA; VPS35 (morris2024thepathogenesisof pages 1-4, alvarez2024acomprehensiveapproach pages 2-4).
- GO Biological Processes: mitophagy (GO:0000423); autophagy (GO:0006914); synaptic vesicle cycle (GO:0099504); axonal transport (GO:0098930); calcium ion homeostasis (GO:0006874); response to oxidative stress (GO:0006979); innate immune response (GO:0045087) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4).
- GO Cellular Components: presynapse (GO:0098793); mitochondrion (GO:0005739); lysosome (GO:0005764); endosome (GO:0005768); Lewy body (GO:0097418) (morris2024thepathogenesisof pages 4-7).
- Cell Types (CL): dopaminergic neuron, SNpc (CL:0002609); microglial cell (CL:0000129); astrocyte (CL:0000127); enteric neuron (CL:0000700) (morris2024thepathogenesisof pages 1-4).
- Anatomy (UBERON): substantia nigra pars compacta (UBERON:0002038); striatum (UBERON:0002435); olfactory bulb (UBERON:0002312); dorsal motor nucleus of vagus (UBERON:0002826); enteric nervous system (UBERON:0007250) (morris2024thepathogenesisof pages 1-4).
- Chemical Entities (CHEBI): dopamine (CHEBI:18243); glucosylceramide (CHEBI:18238); representative therapeutic classes: LRRK2 kinase inhibitors; α‑synuclein immunotherapies (bai2025updatesonparkinson’s pages 1-2, morris2024thepathogenesisof pages 1-4).

Direct supporting statements (quotes)
- “Abnormal alpha‑synuclein aggregation and spreading between gut, brainstem and higher brain regions [is] a likely substrate for disease initiation and progression.” (The Lancet, Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4)
- “Cellular mechanisms implicated across monogenic and sporadic PD include mitochondrial, lysosomal and endosomal dysfunction, and maladaptive immune/inflammatory responses.” (The Lancet, Jan 2024, ibid.) (morris2024thepathogenesisof pages 1-4)
- “There are currently no disease‑modifying treatments, but mechanistic insights… provide a basis for targeted neuroprotective strategies.” (The Lancet, Jan 2024, ibid.) (morris2024thepathogenesisof pages 1-4)
- Reviews from 2025 emphasize a biomarker‑based, prevention‑trial framework: “biological definition… integrating in vivo detection of neuronal α‑synuclein aggregation, neurodegeneration and genetics” (Cells, Jul 2025, https://doi.org/10.3390/cells14151161) (tanaka2025parkinson’sdiseasebridging pages 6-7). 

Notes on scope and limitations
- GLP‑1 receptor agonists and other metabolic approaches are active areas, but detailed clinical meta‑analyses were not directly quoted in the evidence items here; we therefore limited claims to pipeline‑level commentary in authoritative reviews (bai2025updatesonparkinson’s pages 1-2). For detailed efficacy estimates, consult recent trial/meta‑analytic papers.

References (with links and dates)
- Morris HR, Spillantini MG, Sue CM, Williams‑Gray CH. The pathogenesis of Parkinson’s disease. The Lancet. 2024 Jan;403:293–304. doi:10.1016/S0140-6736(23)01478-2. https://doi.org/10.1016/S0140-6736(23)01478-2 (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4)
- Bai H, Ma W, Zhu L, et al. Updates on Parkinson’s Disease. Neuropsychiatric Disease and Treatment. 2025 Sep;21:1945–1953. doi:10.2147/ndt.s540718. https://doi.org/10.2147/ndt.s540718 (bai2025updatesonparkinson’s pages 1-2, bai2025updatesonparkinson’s pages 7-8)
- Tanaka M. Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation. Cells. 2025 Jul;14:1161. doi:10.3390/cells14151161. https://doi.org/10.3390/cells14151161 (tanaka2025parkinson’sdiseasebridging pages 6-7, tanaka2025parkinson’sdiseasebridging pages 2-4)
- Álvarez MM, Cano‑Herrera G, Osorio Martínez MF, et al. A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects. International Journal of Molecular Sciences. 2024 Jun;25:7183. doi:10.3390/ijms25137183. https://doi.org/10.3390/ijms25137183 (alvarez2024acomprehensiveapproach pages 2-4)

Overall synthesis: Contemporary consensus places alpha‑synuclein aggregation/propagation at the core of PD, intersecting with mitochondrial and lysosomal/autophagy dysfunction and immune signaling to produce early synaptic failure and progressive network neurodegeneration. Heterogeneous trajectories (brain‑first, body‑first) map to prodromal markers and likely subtypes. Biomarker advances—especially α‑syn SAA, dopaminergic imaging, and emerging α‑syn PET—support a shift toward biologically defined diagnosis and prevention‑trial designs, while pipelines target α‑syn, LRRK2, lysosome and mitophagy for disease modification. The global burden continues to rise with aging populations, underscoring the urgency of biomarker‑driven, mechanistically informed interventions (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4, bai2025updatesonparkinson’s pages 1-2).

References

1. (morris2024thepathogenesisof pages 1-4): Huw R Morris, Maria Grazia Spillantini, Carolyn M Sue, and Caroline H Williams-Gray. The pathogenesis of parkinson's disease. The Lancet, 403:293-304, Jan 2024. URL: https://doi.org/10.1016/s0140-6736(23)01478-2, doi:10.1016/s0140-6736(23)01478-2. This article has 739 citations and is from a highest quality peer-reviewed journal.

2. (morris2024thepathogenesisof pages 4-7): Huw R Morris, Maria Grazia Spillantini, Carolyn M Sue, and Caroline H Williams-Gray. The pathogenesis of parkinson's disease. The Lancet, 403:293-304, Jan 2024. URL: https://doi.org/10.1016/s0140-6736(23)01478-2, doi:10.1016/s0140-6736(23)01478-2. This article has 739 citations and is from a highest quality peer-reviewed journal.

3. (bai2025updatesonparkinson’s pages 7-8): Hong Bai, Wenhui Ma, Lei Zhu, Yaling Lu, Jiaojiao Fan, Mengjia Chen, and Cong Huang. Updates on parkinson’s disease. Neuropsychiatric Disease and Treatment, Volume 21:1945-1953, Sep 2025. URL: https://doi.org/10.2147/ndt.s540718, doi:10.2147/ndt.s540718. This article has 1 citations and is from a peer-reviewed journal.

4. (alvarez2024acomprehensiveapproach pages 2-4): Mauricio Muleiro Alvarez, Gabriela Cano-Herrera, María Fernanda Osorio Martínez, Joaquin Vega Gonzales-Portillo, Germán Rivera Monroy, Renata Murguiondo Pérez, Jorge Alejandro Torres-Ríos, Ximena A. van Tienhoven, Ernesto Marcelo Garibaldi Bernot, Felipe Esparza Salazar, and Antonio Ibarra. A comprehensive approach to parkinson’s disease: addressing its molecular, clinical, and therapeutic aspects. International Journal of Molecular Sciences, 25:7183, Jun 2024. URL: https://doi.org/10.3390/ijms25137183, doi:10.3390/ijms25137183. This article has 51 citations and is from a poor quality or predatory journal.

5. (tanaka2025parkinson’sdiseasebridging pages 6-7): Masaru Tanaka. Parkinson’s disease: bridging gaps, building biomarkers, and reimagining clinical translation. Cells, 14:1161, Jul 2025. URL: https://doi.org/10.3390/cells14151161, doi:10.3390/cells14151161. This article has 16 citations and is from a poor quality or predatory journal.

6. (chaudhary2025understandingparkinson’sdisease pages 2-3): Sameer A. Chaudhary, Sapana Chaudhary, and Sakshi Rawat. Understanding parkinson’s disease: current trends and its multifaceted complications. Frontiers in Aging Neuroscience, Sep 2025. URL: https://doi.org/10.3389/fnagi.2025.1617106, doi:10.3389/fnagi.2025.1617106. This article has 1 citations and is from a peer-reviewed journal.

7. (bai2025updatesonparkinson’s pages 1-2): Hong Bai, Wenhui Ma, Lei Zhu, Yaling Lu, Jiaojiao Fan, Mengjia Chen, and Cong Huang. Updates on parkinson’s disease. Neuropsychiatric Disease and Treatment, Volume 21:1945-1953, Sep 2025. URL: https://doi.org/10.2147/ndt.s540718, doi:10.2147/ndt.s540718. This article has 1 citations and is from a peer-reviewed journal.

8. (tanaka2025parkinson’sdiseasebridging pages 2-4): Masaru Tanaka. Parkinson’s disease: bridging gaps, building biomarkers, and reimagining clinical translation. Cells, 14:1161, Jul 2025. URL: https://doi.org/10.3390/cells14151161, doi:10.3390/cells14151161. This article has 16 citations and is from a poor quality or predatory journal.